Financial Performance - The company reported revenue of RMB 3,162,415,000 for the year ended December 31, 2024, representing a growth of 2.4% compared to RMB 3,088,387,000 in 2023[6] - Gross profit increased by 11.8% to RMB 751,173,000 from RMB 671,701,000 year-on-year[5] - Net profit for the year rose by 12.2% to RMB 266,034,000, up from RMB 237,126,000 in the previous year[6] - Adjusted net profit attributable to the owners of the parent company was RMB 274,246,000, a 4.2% increase from RMB 263,161,000[5] - Total revenue for the year ended December 31, 2024, was RMB 3,162,415 thousand, an increase from RMB 3,088,387 thousand in 2023, representing a growth of approximately 2.4%[22] - Revenue from mainland China accounted for RMB 3,154,904 thousand, up from RMB 3,075,304 thousand in the previous year, indicating a growth of about 2.6%[22] - Revenue from other regions decreased to RMB 7,511 thousand in 2024 from RMB 13,083 thousand in 2023, reflecting a decline of approximately 42.5%[22] - Revenue from sales of trade goods was RMB 2,946,782 thousand, up from RMB 2,898,390 thousand, reflecting a growth of 1.7%[25] - The pre-tax profit for 2024 was RMB 260,420 thousand, an increase from RMB 238,163 thousand in 2023[36] - Total tax expenses for 2024 amounted to RMB 135,743 thousand, up from RMB 102,203 thousand in 2023, representing a 33.0% increase[29] - Adjusted profit under non-GAAP for the year was RMB 280,413,000, an increase of RMB 18,289,000 or 7.0% compared to the same period in 2023[55] - EBITDA was RMB 475,956,000, up 19.6% from RMB 397,928,000[65] - The gross margin improved to 23.8%, up 2.1 percentage points from 21.7%[65] - The net profit margin increased to 8.4%, up 0.7 percentage points from 7.7%[65] Assets and Liabilities - The total assets less current liabilities amounted to RMB 3,977,215,000, compared to RMB 3,585,930,000 in 2023[10] - Cash and cash equivalents increased to RMB 1,774,358,000 from RMB 1,224,786,000, indicating improved liquidity[10] - Inventory levels rose to RMB 1,236,751,000, up from RMB 1,109,554,000, reflecting increased stock[10] - The company’s total equity increased to RMB 3,761,186,000 from RMB 3,385,889,000 year-on-year[11] - The company’s financing costs rose to RMB 35,979,000 from RMB 21,040,000, indicating higher borrowing costs[8] - Non-current assets totaled RMB 1,776,170 thousand as of December 31, 2024, slightly increasing from RMB 1,770,653 thousand in 2023[23] - The group's net current assets increased to RMB 2,169,969,000 as of December 31, 2024, compared to RMB 386,878,000 as of December 31, 2023[90] - The group's debt-to-asset ratio as of December 31, 2024, was 13.3%, compared to 6.7% as of December 31, 2023[100] Dividends and Shareholder Information - The company did not recommend the distribution of a final dividend for the fiscal year 2024[7] - The company did not propose any dividends for the year ending December 31, 2024[31] - The board has resolved not to recommend a final dividend for the reporting period, compared to a previous dividend of HKD 0.06209 per share[102] Operational Highlights - The company installed 6,763 Hemostasis analyzers in hospitals and medical institutions across China as of December 31, 2024[43] - The company has a distribution network covering 31 provinces, municipalities, and autonomous regions in China, with 351 direct customers and 1,253 distributors[45] - The company aims to expand its product portfolio and distribution network to capture high growth potential in the IVD market[50] - Plans to enhance hospital solution services through data-driven operational models and automation tools to improve efficiency[51] - The company will increase R&D investment focusing on mass spectrometry, molecular diagnostics, and microbiology[52] Research and Development - Research and development costs for 2024 were RMB 7,402 thousand, a decrease from RMB 8,665 thousand in 2023, indicating a reduction of 14.6%[27] - The company received government subsidies totaling RMB 15,524 thousand in 2024, slightly down from RMB 15,996 thousand in 2023[25] Corporate Governance - Ernst & Young resigned as the company's auditor on October 28, 2024, and Daxin Ma Shi Yun Certified Public Accountants was appointed as the new auditor from the same date[107] - The board composition changed during the reporting period, with several new appointments and resignations of directors, effective from various dates in 2024[109] - The company has complied with the public float requirement, maintaining at least 25% of its issued share capital held by the public throughout the reporting period[118] - The company has adopted the standard code of conduct for securities transactions by directors as per the listing rules[115] - The company confirmed that all directors complied with the standard code of conduct throughout the reporting period[116] Market Outlook - The Chinese IVD market is expected to reach RMB 278.7 billion by 2027, with a compound annual growth rate of 15.7% from 2021 to 2027[48] - The company is closely monitoring AI technology advancements and their potential impact on the industry landscape[49] - The establishment of Goheal Technology Limited in Hong Kong marks the company's entry into the AI sector, aiming for scalable deployment of AI technologies[53] - The company is actively exploring cross-industry technology synergies to develop forward-looking technological capabilities[54] Miscellaneous - The company completed a placement of 270,918,016 shares at HKD 0.7 per share, raising approximately RMB 173,142,000[41] - The total capital expenditure during the reporting period was RMB 67,103,000, primarily for the procurement of properties, plants, and equipment[96] - The total employee compensation expenses amounted to RMB 221,693,000 during the reporting period, an increase from RMB 183,869,000 in the previous year[103] - The company has not engaged in any significant acquisitions or disposals of subsidiaries, associates, or joint ventures during the reporting period[114] - The company announced that its shares were suspended from trading on April 1, 2025, and it has applied to resume trading on April 14, 2025[121] - The company will publish its annual report and notice of the annual general meeting in accordance with the listing rules[120]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任 何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 IVD Medical Holding Limited 華 檢 醫 療 控 股 有 限 公 司 （ 於 開 曼 群 島 註 冊 成 立 之 有 限 公 司 ） （股份代號：1931） 董事會會議日期、 有關延遲刊發截至二零二四年十二月三十一日止年度 經審核年度業績的更新 及 暫停買賣 本公告乃由華檢醫療控股有限公司（「本公司」，連同其附屬公司統稱「本集團」） 根據香港聯合交易所有限公司（「聯交所」）證券上市規則（「上市規則」）第13.09(2)(a) 條及第13.49(3)(i)條以及香港法例第571章證券及期貨條例第XIVA部項下的內幕消 息條文（定義見上市規則）作出。 茲提述本公司日期為二零二五年二月十七日、二零二五年二月二十日及二零二五 年三月十一日有關更換核數師的公告（「先前公告」）。 董事會會議日期及有關延遲刊發經審核年度業績的更新 根據上市規則第13.49(3) 條，發行人如未能公佈其初步業 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任 何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 除本公告所披露者外，該等公告及補充公告的其他內容保持不變。本公告乃該等 公告及補充公告之補充，應與該等公告及補充公告一併閱讀。 承董事會命 IVD Medical Holding Limited 華 檢 醫 療 控 股 有 限 公 司 （ 於 開 曼 群 島 註 冊 成 立 之 有 限 公 司 ） （股份代號：1931） 有關核數師辭任的補充公告 茲提述華檢醫療控股有限公司（「本公司」）日期為二零二五年二月十七日及二零 二五年二月二十日的公告，內容分別有關本公司核數師辭任及委任本公司核數師， 以及本公司日期為二零二五年三月十一日的補充公告，內容有關核數師辭任（「補 充公告」）。除非文義另有所指，否則本公告所用詞彙與補充公告所界定者具有相 同涵義。 本公司有意就致使香港大華馬施雲辭任的詳細原因提供以下補充資料： 於補充公告所披露的事件發生前，本集團一名過往數年負責監督本集團會計及審 計相關事宜的財務部高級 ...

本公司有意就致使香港大華馬施雲辭任的詳細原因提供以下補充資料： 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任 何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 IVD Medical Holding Limited 華 檢 醫 療 控 股 有 限 公 司 （ 於 開 曼 群 島 註 冊 成 立 之 有 限 公 司 ） （股份代號：1931） 有關核數師辭任的補充公告 茲提述華檢醫療控股有限公司（「本公司」）日期分別為二零二五年二月十七日及 二零二五年二月二十日的公告，內容分別有關本公司核數師辭任及委任本公司核 數師（「該等公告」）。除非文義另有所指，否則本公告所用詞彙與該等公告所界定 者具有相同涵義。 何鞠誠 香港，二零二五年三月十一日 於二零二五年二月中旬，得悉香港大華馬施雲期望本公司提供額外資料（「尚未提 供的資料」），而本公司管理層認為已向香港大華馬施雲提供該等資料。管理層嘗 試就尚未提供的資料的必要及提供通過與香港大華馬施雲積極討論以解決雙方於 理解及期望上的分歧。然而，香港大華馬施雲堅稱 ...

IVD Medical Holding Limited 華 檢 醫 療 控 股 有 限 公 司 （ 於 開 曼 群 島 註 冊 成 立 之 有 限 公 司 ） （股份代號：1931） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任 何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 除上文所披露者外，於本公告日期，本公司並無任何其他根據上市規則須予披露 的內幕消息。 由於預期延遲刊發二零二四年年度業績，故預計董事會會議將延期舉行以考慮及 批准（其中包括）二零二四年年度業績。本公司將適時公佈董事會會議日期。 (1)委任核數師及 (2)可能延遲刊發二零二四年年度業績 本公告乃由華檢醫療控股有限公司（「本公司」）根據香港聯合交易所有限公司（「聯 交所」）證券上市規則（「上市規則」）第13.51(4)條及香港法例第571章證券及期貨條 例第XIVA部項下的內幕消息條文（定義見上市規則）以及上市規則第13.09(2)(a)及 13.51(4)條作出。 茲提述本公司日期為二零二五年二月十七日的公告（「該公告」）， ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任 何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 IVD Medical Holding Limited 華 檢 醫 療 控 股 有 限 公 司 （ 於 開 曼 群 島 註 冊 成 立 之 有 限 公 司 ） （股份代號：1931） 1 董事會認為，委聘另一家核數師符合本公司及股東的最佳利益，以便股東及投資 者盡快獲得本集團截至二零二四年十二月三十一日止年度的業績。本公司現正物 色合適的繼任者，以填補辭任後的臨時空缺。本公司將根據上市規則適時就委任 新核數師作出進一步公告。 承董事會命 華檢醫療控股有限公司 主席及執行董事 核數師辭任 本公告乃由華檢醫療控股有限公司（「本公司」，連同其附屬公司統稱「本集團」） 根據香港聯合交易所有限公司證券上市規則（「上市規則」）第13.51(4)條作出。 本公司董事（「董事」）會（「董事會」）謹此宣佈，大華馬施雲會計師事務所有限公 司（「香港大華馬施雲」）已辭任本公司核數師，自二零二五年二月十七日起生效（「辭 任」） ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任 何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 IVD Medical Holding Limited 華 檢 醫 療 控 股 有 限 公 司 （ 於 開 曼 群 島 註 冊 成 立 之 有 限 公 司 ） （股份代號：1931） 持續關連交易及 關連交易 重續租賃交易 重續租賃交易 茲提述本公司日期為二零二一年十二月三十一日的公告，內容有關本集團截至 二零二四年十二月三十一日止三個年度，向創始集團及新華醫療集團租賃物業。 本集團預計與創始集團及新華醫療集團的租賃交易於二零二四年十二月三十一 日後將繼續進行或將訂立。於二零二四年十二月三十一日，(i)本公司與何先生、 梁先生及林先生訂立創始集團租賃框架協議及(ii)上海威士達（本集團的成員公司） 與上海新華訂立新華醫療租賃協議。 上市規則之涵義 創始集團租賃框架協議 何先生、梁先生及林先生為本公司關連人士，根據上市規則第14A章，訂立創始 集團租賃框架協議及其項下擬進行的交易構成本公司的持續關連交易。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任 何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 IVD Medical Holding Limited 華 檢 醫 療 控 股 有 限 公 司 （ 於 開 曼 群 島 註 冊 成 立 之 有 限 公 司 ） （股份代號：1931） 諒解備忘錄之訂約各方須盡快就建議投資的相關方訂立之正式買賣協議（「正式協 議」）之條款及條件進行真誠磋商。 1 可退還按金 自願性公告 建議投資目標公司 及申請於場外交易市場進行跨境交易 本公告乃由華檢醫療控股有限公司（「本公司」，連同其附屬公司統稱「本集團」） 自願作出，旨在向本公司股東及有意投資者提供有關本集團近期發展的最新資料。 建議投資目標公司 本公司董事（「董事」）會（「董事會」）欣然宣佈，於二零二四年十二月三十日（交易 時段後），本公司與Believe In AI Technology Limited（「賣方」）就本公司（或其代名 人）建議透過收購一間私人公司（「目標公司」，連同其附屬公司統稱為「目標集團」） ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任 何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 IVD Medical Holding Limited 華 檢 醫 療 控 股 有 限 公 司 （ 於 開 曼 群 島 註 冊 成 立 之 有 限 公 司 ） （股份代號：1931） 更換核數師 本公告乃由華檢醫療控股有限公司（「本公司」，連同其附屬公司統稱「本集團」） 根據香港聯合交易所有限公司（「聯交所」）證券上市規則第13.51(4)條作出。 核數師辭任 本公司董事（「董事」）會（「董事會」）謹此宣佈，其已就更換核數師知會安永會計 師事務所（「安永」）。安永已辭任本公司核數師，自二零二四年十月二十八日起生 效，原因為本公司與安永未能就截至二零二四年十二月三十一日止年度的建議審 計費用達成共識。 安永已作出書面確認，除因本集團的營運規模令審計工作量增加導致審計費用分 歧外，並無有關其辭任之其他情況須提請本公司股東（「股東」）垂注。董事會及本 公司審核委員會（「審核委員會」）亦均已確認，除上文所披露者 ...

Financial Performance - For the six months ended June 30, 2024, the company reported revenue of RMB 1,353,470,000, a decrease of 1.7% compared to RMB 1,377,314,000 in the same period of 2023[5] - The gross profit for the same period increased by 7.7% to RMB 324,692,000, up from RMB 301,540,000 in 2023[5] - The net profit for the period rose by 22.7% to RMB 127,566,000, compared to RMB 104,002,000 in the previous year[6] - Profit attributable to equity holders of the parent increased by 21.6% to RMB 125,288,000 from RMB 103,009,000[5] - The adjusted profit for the period, a non-GAAP measure, was RMB 127,790,000, reflecting an 8.9% increase from RMB 117,396,000 in 2023[6] - Basic and diluted earnings per share for the period were RMB 9.27, up from RMB 7.62, representing an increase of 1.65[5] - The company reported an operating loss of RMB 5,012,000 from its proprietary brand product business, which is still in the early research stage, but this loss did not significantly impact overall financial performance[11] - The gross profit margin improved to 24.0%, up by 2.1 percentage points from 21.9% in the previous year[18] - The net profit for the reporting period was RMB 127,566,000, a 22.7% increase from RMB 104,002,000 for the six months ended June 30, 2023, mainly due to the increase in after-sales service gross profit margin[39] - The adjusted net profit for the reporting period was RMB 127,790,000, an increase of 8.9% from RMB 117,396,000 in the previous period, also driven by the increase in after-sales service gross profit margin[40] Revenue Breakdown - Distribution business revenue was RMB 1,253,634,000, accounting for 92.7% of total revenue, down 3.0% from RMB 1,293,002,000[22] - Revenue from solution services provided to clinical laboratories in hospitals reached RMB 117,462,000, a 4.7% increase from RMB 112,227,000 for the six months ended June 30, 2023[9] - Revenue from the sale of medical consumables was RMB 1,170,596,000, an increase of 1.2% from RMB 1,156,622,000 in the previous year[83] - Revenue from after-sales services increased significantly to RMB 95,258,000, up 22% from RMB 78,163,000 in the prior year[83] - Revenue from sales to hospitals and medical institutions was RMB 188,124,000, an increase from RMB 171,061,000 in the previous year[83] Market Position and Strategy - The company is a leading distributor of IVD products in China and is involved in the research, development, production, and sales of its own brand IVD products[7] - The company aims to stabilize and increase market share and profitability through a competitive and diversified product portfolio and extensive distribution network[7] - The company continues to focus on expanding its market presence and enhancing its product offerings in the IVD sector[7] - The company plans to expand its product portfolio and distribution network to capture high growth potential in the IVD market[14] - The company aims to enhance its R&D capabilities by investing in equipment and hiring experts to develop proprietary IVD products[16] Assets and Liabilities - Cash and cash equivalents increased by 29.8% to RMB 1,589,593,000 compared to RMB 1,224,786,000 at the end of 2023[19] - The total assets of the company rose by 11.3% to RMB 5,328,067,000 from RMB 4,785,052,000[19] - The net current assets increased to RMB 1,829,422,000 as of June 30, 2024, compared to RMB 1,783,091,000 as of December 31, 2023, reflecting an increase of RMB 46,331,000[45] - The group's debt-to-asset ratio was approximately 15.0% as of June 30, 2024, significantly up from 6.7% as of December 31, 2023[54] - The total liabilities as of June 30, 2024, were RMB 259,617,000, a decrease from RMB 330,790,000 as of December 31, 2023, reflecting a reduction of approximately 21.5%[95] Shareholder Information - The total issued and paid-up share capital is 1,354,590,080 shares, with a par value of USD 0.0005 per share, equivalent to RMB 4,637,000[97] - The company has a total of 175,517,429 shares held by KS&KL Investment Co. Limited, representing 12.96% of the issued shares[106] - The company’s major shareholder, King Sun Limited, also holds 175,517,429 shares, accounting for 12.96% of the issued shares[108] - The total shares held by the directors and major executives amount to 465,185,899 shares collectively[107] - The company’s shareholding structure indicates significant control by a few major shareholders, which may impact future strategic decisions[108] Employee Stock Option Plan - The employee stock option plan allows for the issuance of up to 32,507,627 shares, representing 5% of the total issued shares at the time, aimed at attracting and retaining top talent[117] - The management of the employee stock option plan is vested in the board or a committee authorized by the board, ensuring compliance with applicable laws and company regulations[118] - The total number of unexercised stock options as of the interim report date is 19,504,576, representing approximately 0.96% of the total issued shares[128] - The stock option plan is effective for ten years from July 12, 2019, unless terminated earlier by the shareholders or the board[132] - The employee stock option plan is designed to reward employees and promote the overall success of the group, aligning employee interests with company performance[116] Corporate Governance - The company has complied with all applicable corporate governance code provisions except for the separation of the roles of Chairman and CEO[146] - The audit committee reviewed the interim report and found the financial statements to be prepared in accordance with applicable accounting standards[148] - The board composition has changed with several new appointments and resignations during the reporting period[151][152] - The company has adopted a standard code for securities transactions by directors, and all directors confirmed compliance during the reporting period[145] Future Outlook - The Chinese IVD market is projected to reach RMB 278.7 billion by 2027, with a compound annual growth rate (CAGR) of 15.7% from 2021 to 2027[12] - The company is actively exploring business cooperation opportunities, including technology exchanges, to enhance its market competitiveness[16] - The company signed a strategic cooperation agreement with Sysmex in 2023 to deepen collaboration and revise distribution rights, transitioning to long-term distribution rights in specific regions[8]